Ciclopirox 1% shampoo for the treatment of seborrheic dermatitis

International Journal of Dermatology

Volumn 45, Issue 1, 2006, Pages 66-69

  Gupta, Aditya K ^a,b,c   Nicol, Karyn A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYPYRIDINE DERIVATIVE; CICLOPIROX; SHAMPOO; COSMETIC; PYRIDONE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALASSEZIA; META ANALYSIS; MYCOSIS; PATHOPHYSIOLOGY; PREPUTIAL GLAND; SEBORRHEIC DERMATITIS; SKIN DISEASE; SKIN MANIFESTATION; SYSTEMATIC REVIEW; YEAST; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; DERMATITIS, SEBORRHEIC; FEMALE; FOLLOW-UP STUDIES; HAIR PREPARATIONS; HUMANS; MALE; PYRIDONES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33645964646     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02331.x     Document Type: Article

References (32)

1. Crespo Erchiga V, Ojeda Martos A, Vera Casano A, et al. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol 2000; 143: 799-803.
2. Farthing CF, Staughton RC, Rowland Payne CM. Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease. Clin Exp Dermatol 1985; 10: 3-12.
3. Smith KJ, Skelton HG, Yeager J, et al. Cutaneous findings in HIV-1-positive patients: A 42-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol 1994; 31: 746-754.
4. Binder RL, Jonelis FJ. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 1983; 119: 473-475.
5. Faergemann J, Fredriksson T. Tinea versicolor with regard to seborrheic dermatitis. An epidemiological investigation. Arch Dermatol 1979; 115: 966-968.
6. Maietta G, Fornaro P, Rongioletti F, et al. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol 1990; 70: 432-434.
7. Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol 1983; 63: 335-339.
8. Pierard GE. Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology 2003; 206: 187-188.
9. Danby FW, Maddin WS, Margesson LJ, et al. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29: 1008-1012.
10. Ford GP, Farr PM, Ive FA, et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111: 603-607.
11. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49: 145-147.
12. Scaparro E, Quadri G, Virno G, et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001; 144: 854-857.
13. Vardy DA, Zvulunov A, Tchetov T, et al. A double-blind, placebo-controlled trial of a ciclopirox olamine 1% shampoo for the treatment of scalp seborrheic dermatitis. J Dermatol Treat 2000; 11: 73-77.
14. Bergbrant IM, Johansson S, Robbins D, et al. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol 1991; 16: 331-338.
15. Midgley G, Hay RJ. Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and western blotting. Bull Soc Fr Mycol Med 1988; 17: 267-276.
16. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139: 254-263.
17. Faergemann J, Bergbrant IM, Dohse M, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: Characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144: 549-556.
18. Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin 2003; 21: 401-412.
19. Korting HC, Grundmann-Kollmann M. The hydroxypyridones: A class of antimycotics of its own. Mycoses 1997; 40: 243-247.
20. del Palacio-Hernanz A, Guarro-Artigas J, Figueras-Salvat MJ, et al. Changes in fungal ultrastructure after short-course ciclopiroxolamine therapy in pityriasis versicolor. Clin Exp Dermatol 1990; 15: 95-100.
21. Abrams BB, Hanel H, Hoehler T. Ciclopirox olamine: A hydroxypyridone antifungal agent. Clin Dermatol 1991; 9: 471-477.
22. Gupta AK, Skinner AR. Ciclopirox for the treatment of superficial fungal infections: A review. Int J Dermatol 2003; 42 (Suppl. 1): 3-9.
23. Gupta AK. Ciclopirox: An overview. Int J Dermatol 2001; 40: 305-310.
24. Hanel H, Smith-Kurtz E, Pastowsky S. [Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect]. Mycoses 1991; 34 (Suppl. 1): 91-93.
25. Altmeyer P, Plott T. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: Results of a randomized, double blind, vehicle-controlled trial. Int J Dermatol 2004; in press.
26. Abeck D. Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: Results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J Dermatol 2004; in press.
27. Lebwohl M. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; in press.
28. Dupuy P, Maurette C, Amoric JC, et al. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144: 1033-1037.
29. Unholzer A, Varigos G, Nicholls D, et al. Ciclopiroxolamine cream for treating seborrheic dermatitis: A double-blind parallel group comparison. Infection 2002; 30: 373-376.
30. Aly R, Katz HI, Kempers SE, et al. Ciclopirox gel for seborrheic dermatitis of the scalp. Int J Dermatol 2003; 42 (Suppl. 1): 19-22.
31. Shuttleworth D, Squire RA, Boorman GC, et al. Comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) or ketoconazole (2%, Nizoral) for the control of dandruff/seborrheic dermatitis. J Dermatol Treat 1998; 9: 157-162.
32. Squire RA, Goode K. A randomized, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatol Treat 2002; 13: 51-60.